Effects of oxcarbazepine and carbamazepine on driving ability: A double-blind, randomized crossover trial with healthy volunteers

Psychopharmacology

Volumn 210, Issue 1, 2010, Pages 53-63

  Kaussner, Yvonne ^a   Kenntner Mabiala, Ramona ^b   Hoffmann, Sonja ^b   Klatt, Jan ^c   Tracik, Ferenc ^c   Krüger, Hans Peter ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b WIVW Center for Traffic Science   (Germany)

^c NOVARTIS PHARMA GMBH   (Germany)

Author keywords

Anticonvulsant; Antiepileptic drugs (AED); Driving fitness; Driving simulator; Randomized clinical trial

Indexed keywords

CARBAMAZEPINE; CREATININE; OXCARBAZEPINE;

ABNORMAL SENSATION; ADULT; ARTICLE; ATTENTION; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRIVING ABILITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; EPILEPSY; EVENING DOSAGE; EYELID CLOSURE; FEMALE; HUMAN; HUMAN EXPERIMENT; LYMPHOCYTE COUNT; MALE; MORNING DOSAGE; MOTOR PERFORMANCE; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SIMULATION; SOMNOLENCE; TASK PERFORMANCE;

ADULT; AUTOMOBILE DRIVING; CARBAMAZEPINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PHOTIC STIMULATION; PSYCHOMOTOR PERFORMANCE; REACTION TIME; YOUNG ADULT;

EID: 77955570064     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1814-y     Document Type: Article

References (14)

1. Aldenkamp AP, De Krom M, Reijs R (2003) Newer antiepileptic drugs and cognitive issues. Epilepsia 44:21-29
2. Brenner-Hartmann J, Bukasa B (2002) Durchführung standardisierter Fahrverhaltensbeobachtungen im Rahmen der medizinischpsychologischen Untersuchung (MPU) BDP-Kongress für Verkehrspsychologie, Regensburg
3. Curran HV, Java R (1993) Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. Clin Pharm 44:529-533
4. Dam M, Ekberg R, Loining Y, Waltimo O, Jakobsen K (1989) A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 3:70-76
5. de Gier H (2006) Medicinal drugs. Critical review of present knowledge and statements for discussion transportation research circular. Drugs and traffic. A symposium. Woods Hole, Massachusetts, pp 67-77
6. Drazkowsky JF (2007) Driving and flying with epilepsy. Curr Neurol Neurosci Rep 7:329-334
7. Hargutt V (2003) Das Lidschlussverhalten als Indikator für Aufmerksamkeits-und Müdigkeitsprozesse bei Arbeitshandlungen. VDI-Verlag, VDI-Verlag
8. Hoffmann S, Buld S (2006) Darstellung und Evaluation eines Trainings zum Fahren in der Fahrsimulation. VDI-Gesellschaft Fahrzeug-und Verkehrstechnik. Integrierte Sicherheit und Fahrerassistenzsysteme (VDI-Bericht Nr. 1960). VDI-Verlag, pp 113-132
9. Martin R, Vogtle L, Gilliam F, Faught E (2005) What are the concerns of older adults living with epilepsy? Epilepsy Behav 7:297-300
10. Michon JA (1989) Explanatory pitfalls and rule-based driver models. Accid Anal Prev 21:341-353
11. Ramaekers JG, Lamers CTJ, Verhey F, Muntjewerff ND, Mobbs E, Sanders N, Lewis JM, Lockton JA (2002) A comparative study of the effects of carbamazepine and the NMDA receptor antagonist remacemide on road tracking and car-following performance in actual traffic. Psychopharmacology 159:203-210
12. Schmidt E, Elger CE (2004) Worin unterscheidet sich Oxcarbazepin von Carbamazepin? Differences between oxcarbazepine and carbamazepine. der Nervenarzt 75:153-160
13. Valmain J, Darde JB, Gappmaeier B, Kirker J, Kraemer G, Markschies N, Ojala M, et al. (2005) Epilepsy and driving in Europe. A report of the Second European Working Group on Epilepsy and Driving. European Commision
14. Wesnes KA, Edgar C, Dean ADP, Wroe SJ (2009) The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy. Epilepsy Behav 14:522-528